Cite
HARVARD Citation
Marabelle, A. et al. (n.d.). 316 EVICTION Study: Preliminary results in solid tumor patients with ICT01, a first-in-class, gamma9 delta2 T cell activating antibody targeting butyrophilin-3A. Journal for immunotherapy of cancer. pp. A194-A195. [Online].